EJ-1 Xenograft Model Service for Bladder Cancer

The EJ-1 xenograft model is a well-established preclinical platform for evaluating therapeutic candidates against urothelial bladder cancer, enabling robust assessment of tumor growth inhibition, drug pharmacokinetics, and biomarker modulation in an immunodeficient host environment. Alfa Cytology specializes in the construction and validation of EJ-1 xenograft models, delivering standardized, reproducible tumor systems tailored to support your oncology drug discovery and translational research programs from early-stage screening through advanced efficacy evaluation.

Overview of EJ-1 Xenograft Model for Bladder Cancer

The EJ-1 cell line is a human bladder carcinoma cell line originally derived from a grade II transitional cell carcinoma of the bladder. It exhibits epithelial-like morphology and has been extensively characterized in the literature as sharing an identical genetic profile with the T24 cell line, as confirmed by STR-PCR analysis. EJ-1 cells harbor a Ha-ras oncogene mutation and demonstrate moderate epidermal growth factor receptor (EGFR) expression, making them a representative model for high-grade urothelial carcinoma. When implanted into immunodeficient mice, EJ-1 cells form solid, well-vascularized subcutaneous tumors that closely recapitulate the histological architecture and growth kinetics of human bladder cancer, providing a physiologically relevant system for preclinical therapeutic evaluation.

In xenograft applications, the EJ-1 model has been widely utilized to assess the antitumor efficacy of chemotherapeutic agents, targeted small molecules, monoclonal antibodies, and novel drug delivery systems. Studies have demonstrated that EJ-1 xenografts respond to a range of interventions, including cisplatin-based regimens, natural compound derivatives such as isolinderalactone and peimine, and EGFR-targeted modular nanotransporters. The model supports longitudinal tumor volume monitoring, survival analysis, histopathological examination, and immunohistochemical profiling, offering a versatile and translationally relevant platform for bladder cancer drug development.

Figure 1. Apoptosis induced in EJ-1 cancer cells by fucoxanthin. (Zhang, Z, et al., 2008)

Cell Line Information: EJ-1

The following table summarizes the key characteristics and culture parameters of the EJ-1 human bladder cancer cell line:

Our Services

At Alfa Cytology, we provide comprehensive EJ-1 xenograft model services designed to accelerate your bladder cancer research pipeline. Our experienced team handles every stage of model development---from cell line authentication and quality-controlled expansion to in vivo implantation, tumor monitoring, and endpoint analysis---ensuring that each study is executed with rigorous scientific standards and full traceability. Whether you require single-agent efficacy studies, combination therapy evaluation, or biomarker-driven mechanistic investigations, Alfa Cytology delivers reliable, reproducible data to advance your preclinical oncology programs.

Workflow of EJ-1 Xenograft Model Construction

The construction of an EJ-1 xenograft model follows a systematic, quality-controlled workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data reproducibility. The process encompasses cell preparation, host selection, surgical implantation, tumor monitoring, and endpoint analysis, with each step governed by standardized operating procedures.

1. Cell Line Authentication and Expansion: EJ-1 cells are authenticated via STR profiling to confirm identity and screened for mycoplasma contamination. Cells are expanded under standard culture conditions (EMEM + 10% FBS, 37 degrees C, 5% CO2) to achieve the required cell number for implantation, typically 1--5 x 10^6 cells per injection site.
2. Host Animal Selection and Acclimation: Immunodeficient mice (commonly BALB/c nude or NOD/SCID) aged 6--8 weeks are selected based on study design requirements. Animals undergo a minimum 5--7 day acclimation period with health monitoring to ensure baseline physiological stability prior to tumor cell injection.
3. Cell Harvest and Preparation: Exponentially growing EJ-1 cells are harvested using trypsin-EDTA, washed with PBS, and resuspended in serum-free medium or Matrigel/medium mixture at the designated concentration. Cell viability is confirmed by trypan blue exclusion (>=95% viability required).
4. Subcutaneous Tumor Cell Implantation: Under aseptic conditions, EJ-1 cells are injected subcutaneously into the flank region of the mouse at a 45-degree angle, depositing the cell suspension into the subcutaneous connective tissue layer. Typical injection volume ranges from 100--200 uL per site.
5. Tumor Monitoring and Measurement: Tumor formation is monitored by palpation beginning 7 days post-implantation. Once tumors become palpable, longitudinal measurements are recorded using digital calipers every 2--3 days. Tumor volume is calculated using the formula: V = (length x width^2) / 2.
6. Treatment Administration (Optional): Upon reaching a predetermined tumor volume (typically 100--200 mm^3), animals are randomized into treatment and control groups. Test compounds are administered via the designated route (intraperitoneal, intravenous, or oral gavage) according to the study protocol.
7. Endpoint Analysis and Sample Collection: At study termination, animals are humanely euthanized. Tumors are excised, weighed, and photographed. Tissue samples are processed for histopathology (H&E staining), immunohistochemistry (IHC), Western blot, or molecular analysis as required by the study objectives.

Figure 2. EJ-1 xenograft model construction workflow.

Case Study-EJ-1 Xenograft Model Development

Alfa Cytology has successfully developed and validated the EJ-1 bladder cancer xenograft model for multiple client programs, demonstrating consistent tumor engraftment rates and robust response to reference compounds. In a representative study, EJ-1 cells were implanted subcutaneously into BALB/c nude mice, with palpable tumors established within 10--14 days and reaching evaluable volumes by day 21. Treatment with a reference therapeutic agent resulted in significant tumor growth inhibition compared to vehicle controls, with corresponding reductions in tumor weight and favorable histopathological outcomes. Detailed quantitative data---including tumor growth curves, body weight monitoring, and biomarker expression profiles---are available upon request under confidentiality agreements. Please contact our scientific team to discuss your specific study requirements and to access comprehensive case study documentation.

Why Choose Alfa Cytology?

Alfa Cytology is committed to delivering high-quality, scientifically rigorous preclinical tumor model services that empower your oncology research. Our EJ-1 xenograft model service is distinguished by the following advantages:

• Validated cell line authentication via STR profiling ensures genetic fidelity and traceability for every study.
• Standardized operating procedures guarantee reproducible tumor engraftment, growth kinetics, and treatment response across independent experiments.
• Flexible study designs accommodate single-agent efficacy, combination therapy, dose-response, and biomarker-driven mechanistic investigations.
• Comprehensive endpoint analysis includes tumor volume tracking, body weight monitoring, histopathology, immunohistochemistry, and molecular profiling.
• Experienced in vivo team with expertise in immunodeficient mouse models, ensuring animal welfare compliance and data integrity.
• Rapid project turnaround with dedicated project management and transparent communication throughout the study lifecycle.

Contact Us

Ready to advance your bladder cancer research with a validated EJ-1 xenograft model? Contact us today to discuss your project requirements, receive a customized study proposal, and learn how Alfa Cytology can support your preclinical drug development goals. Our scientific team is available to answer your questions and guide you through every stage of model design and execution. Please reach out to us today via our inquiry form or email to learn more about our EJ-1 Xenograft Model services.

For research use only. Not intended for any clinical use.